Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126644162 | 12664416 | 2 | F | 20160801 | 20160828 | 20160818 | 20160909 | EXP | IL-TEVA-684038ACC | TEVA | 43.77 | YR | F | Y | 0.00000 | 20160909 | CN | IL | IL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126644162 | 12664416 | 1 | PS | PROVIGIL | MODAFINIL | 1 | Oral | 100 MILLIGRAM DAILY; | Y | 20717 | 100 | MG | QD | ||||||
| 126644162 | 12664416 | 2 | C | COPAXONE | GLATIRAMER ACETATE | 1 | Subcutaneous | 20 MILLIGRAM/MILLILITERS DAILY; | 0 | INJECTION | QD | ||||||||
| 126644162 | 12664416 | 3 | C | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 150 MILLIGRAM DAILY; | 0 | 150 | MG | QD | |||||||
| 126644162 | 12664416 | 4 | C | ZYPREXA | OLANZAPINE | 1 | Oral | 0 | |||||||||||
| 126644162 | 12664416 | 5 | C | LYRICA | PREGABALIN | 1 | 0 | ||||||||||||
| 126644162 | 12664416 | 6 | C | LOSEC | OMEPRAZOLE | 1 | Oral | 20 MILLIGRAM DAILY; | 0 | 20 | MG | QD | |||||||
| 126644162 | 12664416 | 7 | C | VITAMIN D | CHOLECALCIFEROL | 1 | Oral | 0 | |||||||||||
| 126644162 | 12664416 | 8 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | Oral | 0 | |||||||||||
| 126644162 | 12664416 | 9 | C | IRON | IRON | 1 | Oral | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126644162 | 12664416 | 1 | Product used for unknown indication |
| 126644162 | 12664416 | 2 | Multiple sclerosis |
| 126644162 | 12664416 | 3 | Product used for unknown indication |
| 126644162 | 12664416 | 4 | Product used for unknown indication |
| 126644162 | 12664416 | 5 | Product used for unknown indication |
| 126644162 | 12664416 | 6 | Product used for unknown indication |
| 126644162 | 12664416 | 9 | Supplementation therapy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126644162 | 12664416 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126644162 | 12664416 | Abdominal pain upper | |
| 126644162 | 12664416 | Asthenia | |
| 126644162 | 12664416 | Breast pain | |
| 126644162 | 12664416 | Hypoaesthesia | |
| 126644162 | 12664416 | Nausea | |
| 126644162 | 12664416 | Tinnitus | |
| 126644162 | 12664416 | Vision blurred |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126644162 | 12664416 | 1 | 20160801 | 20160806 | 0 | |
| 126644162 | 12664416 | 2 | 20121205 | 0 |